VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PFE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PFEPfizer Inc.
$28.46$159.9B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PFE logo

Pfizer Inc.

PFE
NYSE · Big Pharma
$28.46
At close - Nov 17, 4:00 PM EST - USD
Market Cap$162.21B
P/E40.6x
52W High$31.44
Volume35.18M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Pfizer Faces Revenue Plateau as Patent Cliff Nears

Pfizer's top line has stalled, with 2026Q3 revenue of $16.6B reflecting year-over-year growth of -0.4%, suggesting the post-pandemic revenue base is plateauing rather than re-accelerating.

GrowthDecelerating
ProfitabilityModerate
ValuationAttractive
TechnicalsMixed
Explore valuation models
MARKET ACTION

PFE price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

12/12 Beats

EPS beat 12 of last 12 quarters

02

Valuation risk

+34% Peers

P/E is 34% above peer median

03

Market leadership

RS 70 · Avg

Average momentum (RS Rating: 70)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Feb 3
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue has plateaued near $14B-$17B per quarter with 2026Q3 growth of -0.4%, while gross margin swung between 67.3% and 75.7% and operating margin compressed to 21.0% in 2025Q4 from 33.7% in 2025Q1, suggesting operating income is not scaling with gross profit.

Analyst Consensus+10.9% target
Hold(40 analysts)
16 Buy23 Hold1 Sell

The Bull Case

Upside Catalysts

Strong Pipeline Progress

Pfizer's oncology drugs like Padcev, Lorbrena, and Talzenna are performing well, with pivotal trials for weight-loss drugs planned for 2026.

New Product Launches

The company's strategy includes acquiring and developing new products, which could enhance revenue.

Positive Technical Indicators

Technical analyses suggest a potential stabilization above $25.00, with targets of $28.00-$29.00.

The Bear Case

Key Downside Risks

Significant Patent Cliffs

Key products like Eliquis and Ibrance will lose patent protection between 2026 and 2030, potentially impacting revenues by $1.5 billion in 2026.

Declining COVID-19 Sales

Sales from the COVID-19 vaccine and antiviral are expected to decline further in 2026, affecting overall revenue.

Increased Competition

Competition in breast cancer treatments and obesity drugs from companies like Eli Lilly and Novo Nordisk could erode market share.

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PFE+19.86%
S&P 500 (^GSPC)+7.21%
1-Year Return
PFE+20.34%
S&P 500 (^GSPC)+10.03%
3-Year Return
PFE+12.23%
S&P 500 (^GSPC)+60.06%
5-Year Return
PFE-27.62%
S&P 500 (^GSPC)+51.66%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
40.0x
Forward P/EExpansion
9.3x
EV/EBITDA60th %ile
10.4x
FCF YieldCash Flow
7.4%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
40.0x
18.3x
80th· High
EV/EBITDA
10.4x
9.9x
60th· Fair
Price/FCF
13.6x
15.4x
40th· Fair
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$37.84+33.0%
Base (Fair)$70.46+143.9%
Bull$106.43+274.0%
$37.84 Bear$70.46 Base$106.43 Bull
Current Market Price: $28.46
Trades at a 59.6% discount to Base DCF ($70.46)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$62.58B-1.6% YoY
Net income FY25
$7.77B-3.2% YoY
Free cash flow FY25
$9.08B-7.7% YoY
Operating margin FY25
27.8%+4.3 pts YoY
ROIC (FY25)8.5%
Avg ROIC 5Y11.2%
ROE (TTM)4.6%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate12/12 (100%)
Revenue Beat Rate11/12 (92%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 3, 2026
$0.87+18.4%
vs $0.73
$16.6B+4.6%
vs $15.9B
Q3 2026
Aug 4, 2026
$0.77+12.9%
vs $0.68
$15.0B+4.4%
vs $14.4B
Q2 2026
May 5, 2026
$0.75+3.9%
vs $0.72
$14.5B+4.4%
vs $13.8B
Q1 2026
Feb 3, 2026
$0.66+16.4%
vs $0.57
$17.6B+4.2%
vs $16.8B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·13h ago
Pfizer: The Patent Cliff Fears Are Overblown

Pfizer Inc., a Big Pharma player offering a 5.96% dividend yield, remains a controversial choice among long-term retail investors. Most concerns reflect PFE's upcoming patent expiration cycle, which is expected to last about 3 years. However, I believe these fears are overblown given PFE's oncology portfolio, Eliquis, and tafamidis franchise, which delivered strong Q3 performance.

247 Wallst·14h ago
4 Dividend Stocks Yielding Over 6% That Fit a Roth IRA

Four stocks paying over 6% can quietly hand the IRS thousands every year, and one of them gets taxed far harder than the rest. Find out which holding belongs in a Roth first and why the gap keeps growing.

247 Wallst·14h ago
3 High-Yield Dividend Stocks Down Nearly 30% or More in 5 Years

Three famous dividend payers have lost a big chunk of their value since 2020, and two already slashed their payouts. Before chasing the fat yields, income investors should ask which of these beaten-down stocks still has a dividend worth trusting.

Business Wire·16h ago
Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases. Pfizer also receives ri.

Filtered for Pfizer Inc.More Headlines
04

Compare before deciding

Benchmark PFE against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Pfizer Inc. (PFE)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PFE logoPFEPfizer Inc.Current
$28.46$162.21B40.58-1.65%6.34%4.58%6.04%
JNJ logoJNJJohnson & Johnson
$278.70$670.89B42.406.05%16.2%19.55%1.83%
MRK logoMRKMerck & Co., Inc.
$143.37$354.1B145.131.18%3.64%5.29%2.27%
ABBV logoABBVAbbVie Inc.
$292.86$517.42B50.148.57%15.68%—2.24%
LLY logoLLYEli Lilly and Company
$1415.55$1.33T45.8544.7%31.9%83.65%0.42%
BMY logoBMYBristol-Myers Squibb Company
$61.35$125.28B13.63-0.22%18.47%43.84%4.03%

Compare PFE vs Peers

Pfizer Inc. (PFE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs JNJ

Most directly comparable listed peer for PFE.

Scale Benchmark

vs LLY

Larger-name benchmark to compare PFE against a more recognizable public peer.

Peer Set

Compare Top 5

vs JNJ, MRK, ABBV, LLY

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PFE SEC Filings & Documents

Pfizer Inc. (PFE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 3, 2026·SEC

Material company update

Nov 3, 2026·SEC

Material company update

Aug 4, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 3, 2026·SEC

FY 2026

Aug 4, 2026·SEC

FY 2026

May 5, 2026·SEC

Get notified when PFE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PFE Frequently Asked Questions

Pfizer Inc. (PFE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Pfizer Inc.'s revenue?

Pfizer Inc. (PFE) reported $63.62B in revenue over the trailing twelve months. Revenue was $62.58B in fiscal year 2025. That is 454% more than the $11.31B of fiscal year 1996.

How fast is Pfizer Inc. growing?

Pfizer Inc. (PFE) grew revenue by 1.3% over the trailing twelve months, compared with the twelve months before.

Is PFE profitable?

Yes. Pfizer Inc. (PFE) earned $4.03B in net income over the trailing twelve months (a 6.3% net margin).

Dividend & Returns
Does PFE pay dividends?

Yes. Pfizer Inc. (PFE) pays a dividend that yields 6.04% at the current price, a high yield.

What is PFE's return on equity?

Pfizer Inc. (PFE) had a return on equity (ROE) of 4.6% over the trailing twelve months. That is below the market's typical 10-15%.

What is Pfizer Inc.'s free cash flow?

Pfizer Inc. (PFE) generated $11.79B in free cash flow over the trailing twelve months.

What if you invested $1,000 in PFE back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →